» Articles » PMID: 36661847

Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer

Abstract

Therapy resistance is imposing a daunting challenge on effective clinical management of breast cancer. Although the development of resistance to drugs is multifaceted, reprogramming of energy metabolism pathways is emerging as a central but heterogenous regulator of this therapeutic challenge. Metabolic heterogeneity in cancer cells is intricately associated with alterations of different signaling networks and activation of DNA damage response pathways. Here we consider how the dynamic metabolic milieu of cancer cells regulates their DNA damage repair ability to ultimately contribute to development of therapy resistance. Diverse epigenetic regulators are crucial in remodeling the metabolic landscape of cancer. This epigenetic-metabolic interplay profoundly affects genomic stability of the cancer cells as well as their resistance to genotoxic therapies. These observations identify defining mechanisms of cancer epigenetics-metabolism-DNA repair axis that can be critical for devising novel, targeted therapeutic approaches that could sensitize cancer cells to conventional treatment strategies.

Citing Articles

Cancer metabolic reprogramming and precision medicine-current perspective.

Gao T, Yang L, Zhang Y, Bajinka O, Yuan X Front Pharmacol. 2024; 15:1450441.

PMID: 39484162 PMC: 11524845. DOI: 10.3389/fphar.2024.1450441.


The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities.

Cordani M, Michetti F, Zarrabi A, Zarepour A, Rumio C, Strippoli R Neoplasia. 2024; 58:101076.

PMID: 39476482 PMC: 11555605. DOI: 10.1016/j.neo.2024.101076.


Curcumin improves atrial fibrillation susceptibility by regulating tsRNA expression in aging mouse atrium.

Luo X, Liu P, Ye X, He J, Lai Y, Lv Y PeerJ. 2024; 12:e17495.

PMID: 39076782 PMC: 11285363. DOI: 10.7717/peerj.17495.


Mechanism of Histone Arginine Methylation Dynamic Change in Cellular Stress.

Ren X, Li W, Li W, Yu W Int J Mol Sci. 2024; 25(14).

PMID: 39062806 PMC: 11277302. DOI: 10.3390/ijms25147562.


The future of cancer treatment: combining radiotherapy with immunotherapy.

Dagar G, Gupta A, Shankar A, Chauhan R, Macha M, Bhat A Front Mol Biosci. 2024; 11:1409300.

PMID: 39044839 PMC: 11263218. DOI: 10.3389/fmolb.2024.1409300.


References
1.
Hong S, Hwang S, Wang T, Park C, Ryu Y, Jung J . Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level. Cancer Sci. 2018; 110(2):629-638. PMC: 6361564. DOI: 10.1111/cas.13886. View

2.
Syu J, Chi J, Kung H . Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget. 2016; 7(12):14659-72. PMC: 4924742. DOI: 10.18632/oncotarget.7406. View

3.
Chou F, Liu Y, Lang F, Yang C . D-2-Hydroxyglutarate in Glioma Biology. Cells. 2021; 10(9). PMC: 8464856. DOI: 10.3390/cells10092345. View

4.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

5.
Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E . PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016; 27(8):1519-25. PMC: 6279074. DOI: 10.1093/annonc/mdw197. View